RNAnoTher - mRNA, Nanomedicine and Theranostic: From cell signaling to personalized therapy

Encapsulation of Phenazine and Derivatives Thereof 2019.

Barthelemy, P.; Benizri, S.; Branger, N.; Camplo, M.; Karaki, S.; Rocchi, P.; Siri, O. Patent WO2019175163A1, 2020.
The invention demonstrated that the amphiphilic Lipid-modified Antisense Oligonucleotides (L-ASOs) can spontaneously self-assemble into nanoparticle (NP) forming a hydrophobic core to encapsulate chemical compounds and serve as nanocarriers to deliver cytotoxic chemotherapy

ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR THE TREATMENT OF CANCER

Le, T.K., Lannes, F., Benizri, S., Taieb, D., Barthélémy, P. and Rocchi, P. Antisense Oligonucléotides Effective to reduce the expression of DDX5 in cancer cells of a subject. Patent EB19031, 2020.

Nanoparticles comprising a core with a phenazine derivative and a shell with a nucleolipid and uses thereof

Paris, C., Camplo, M., Siri, O. and Rocchi, P*. Nanoparticles comprising a core with a phenazine derivative and a shell with a nucleolipid and uses thereof. Patent BET 16P0495, 2020.

Identification et Ciblage de l’interaction Hsp27-eIF4E

Andrieu, C., Siri, O., Camplo, M., Barthélémy, P., Ziouziou, H., Karaki, S. and Rocchi, P*. Identification et Ciblage de l’interaction Hsp27-eIF4E. European Patent BET 16P0495, 2018

Drug design of ASO sequences for targeting gene involved in human diseases.

Finetti, P., Birnbaum, D., Bertucci, F and Rocchi, P*. Drug design of ASO sequences for targeting gene involved in human diseases. APP program deposit (PDA16130, 2022).

Antisense Oligonucléotides Effective to reduce the expression of Menin in cancer cells of a subject

Cherif, C., Benizri, S., El Kaoutari, A., Barthélémy, P. and Rocchi, P*. Antisense Oligonucléotides Effective to reduce the expression of Menin in cancer cells of a subject, Patent PCT16305135, 2016

Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain

Rocchi, P., Gissot, A., Oumzil, K., Acunzo, J and Barthélémy, P., Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain. Patent PCT 001516 (2013)

Hydrophobically modified antisense oligonucleotides comprising a cetal group

Rocchi, P., Oumzil, K., Acunzo, J and Barthélémy, P**., Hydrophobically modified antisense oligonucleotides comprising a cetal group. patent PCT 001517 (2013).

Nucleic Acid targeting TCTP for use in the treatment of cancer

Baylot, V., Andrieu, C., Acunzo, J., Katsogiannou, M. and Rocchi, P*. Patent PCT10306447.3 (2010). Nucleic Acid targeting TCTP for use in the treatment of cancer.

Compounds inhibiting TP53INP1 activity for the treatment of prostate cancer, and its use in screening and diagnostic methods

Rocchi, P*., Giusano, S., Dusetti, N., Iovanna, J. and Garcia, S. Patent PCT10187564.9 (2010). Compounds inhibiting TP53INP1 activity for the treatment of prostate cancer, and its use in screening and diagnostic methods

Derivatives of phenazines useful to treat cancer.

Seillan, C., Andrieu, C., Iovanna, J., Siri, O. and Rocchi, P*. Patent PCT 10305284.1. (2010). Derivatives of phenazines useful to treat cancer.

Novel Triazole Nucleoside Analogues as Anticancer Candidate.

Xia, Y., Wan, J., Qu, F., Iovanna, L., Peng, L. and Rocchi, P*. Patent PCT 08 155481.8 (2008). Novel Triazole Nucleoside Analogues as Anticancer Candidate.

ompositions and Methods for treatment of Prostate Cancer and Other Solid Cancers.

Rocchi, P*. and Gleave, M. Oncogenex licensed Patent PCT no 10/605, 498 (2005). Compositions and Methods for treatment of Prostate Cancer and Other Solid Cancers.

Our Patents